A high-throughput screen to identify new sympathomimetic compounds was developed such that a transgenic line of cells was created that contained the alpha-1 (red), alpha-2 (yellow), beta-1 (green) and beta-2 (blue) receptors. When each of the receptors was activated a different fluorescent protein was expressed and new compounds with different properties could be identified by the fluorescence that they induced. Compound 7583 selectively induced the expression of the blue fluorescent protein. Which of the following known sympathomimetic medications if administered would similarly result in expression of only the blue fluorescent protein?
Q192
A 53-year-old man is brought by his daughter to the clinic. She lives a town away but visits often. She reports that on recent visits, his mood has been volatile, ranging from aggressive at some moments to depressed at others. She has noticed some new jerky movements which she has never seen before and has been quite forgetful. She is concerned that he might be abusing alcohol and drugs. What changes would you expect in the brain of this patient?
Q193
A 61-year-old man with Alzheimer disease is brought to the emergency department 20 minutes after ingesting an unknown amount of his medications in a suicide attempt. He reports abdominal cramps, diarrhea, diaphoresis, and muscular weakness and spasms in his extremities. His temperature is 38.4°C (101.1°F), pulse is 51/min, respirations are 12/min and labored, and blood pressure is 88/56 mm Hg. Physical examination shows excessive salivation and tearing, and small pupils bilaterally. Treatment with atropine is initiated. Shortly after, most of his symptoms have resolved, but he continues to have muscular spasms. Administration of which of the following is the most appropriate next step in management of this patient?
Q194
A 32-year-old man comes to the physician with involuntary lip smacking and hand and leg movements for the past two weeks. The movements are causing him difficulty walking and functioning at work. He has bipolar disorder treated with fluphenazine. Three months ago, he was hospitalized because of a manic episode, and his dosage was adjusted. Since then, he has not experienced a depressed mood, increased energy, irritability, or a change in his eating or sleeping patterns. He does not have suicidal or homicidal ideation. His temperature is 37.2°C (99°F), pulse is 75/min, and blood pressure is 126/78 mmHg. Examination shows repetitive lip smacking and dance-like hand and leg movements. His speech is not pressured, and his affect is appropriate. He is switched from fluphenazine to risperidone and his symptoms improve. Which of the following mechanisms explains this patient's improvement?
Q195
A 28-year-old man is brought to the emergency department after his girlfriend found him twitching and jerking in the yard while gardening. Shortly after he became obtunded, emergency medical services reported 1 episode of emesis during transport. His blood pressure is 85/50 mmHg, pulse is 55/min, and respirations are irregular. Physical examination demonstrates marks on his left forearm, pinpoint pupils, diaphoresis, and fasciculations of his left calf. Following initial stabilization and respiratory support, what is the best next step?
Q196
A 72-year-old man comes to the physician with his son for a follow-up examination. The son reports that his father's mental status has declined since the previous visit when he was diagnosed with Alzheimer dementia. The patient often begins tasks and forgets what he was doing. He has increased trouble remembering events that occurred the day before and sometimes forgets names of common household objects. He has hypertension and hyperlipidemia. His current medications include lisinopril, hydrochlorothiazide, atorvastatin, and donepezil. He is confused and oriented only to person. He is unable to count serial sevens backward from 100. He is able to register 3 items but unable to recall them 5 minutes later. Which of the following is the most appropriate pharmacotherapy?
Q197
A 45-year-old woman comes to the physician for the evaluation of persistent headaches for the last 2 months. The symptoms started insidiously. Menses had previously occurred at regular 28-day intervals with moderate flow. Her last menstrual period was 12 weeks ago. She is sexually active with her husband but reports decreased interest in sexual intercourse over the past few months. The patient does not smoke or drink alcohol. She is 168 cm (5 ft 6 in) tall and weighs 68 kg (150 lb); BMI is 24 kg/m2. She appears uncomfortable. Vital signs are within normal limits. A urine pregnancy test is negative. A pelvic ultrasound shows atrophic endometrium. A cranial MRI with contrast shows a 2-cm intrasellar mass. A hormone assay is performed and is positive. Which of the following is the most appropriate next step in the management?
Q198
A 27-year-old woman comes to the physician for the evaluation of infertility. She has been unable to conceive for the past 2 years. Menses occur at 45 to 80-day intervals. She is 168 cm (5 ft 6 in) tall and weighs 77 kg (170 lb); BMI is 27.4 kg/m2. Physical examination shows facial acne and pigmented hair on the upper lip. Serum studies show elevated levels of testosterone and an LH:FSH ratio of 4:1. Treatment with the appropriate drug for this patient's infertility is begun. Which of the following is the primary mechanism of action of this drug?
Q199
A 64-year-old man is brought to the emergency department by his wife with a 2-hour history of diarrhea and vomiting. He says that he felt fine in the morning, but noticed that he was salivating, sweating, and feeling nauseated on the way home from his work as a landscaper. The diarrhea and vomiting then started about 10 minutes after he got home. His past medical history is significant for depression and drug abuse. His wife says that he has also been more confused lately and is afraid he may have ingested something unusual. Physical exam reveals miosis, rhinorrhea, wheezing, and tongue fasciculations. Which of the following treatments would most likely be effective for this patient?
Q200
A 65-year-old male who is being treated for depression visits your emergency room complaining of being unable to urinate. In addition, the patient complains of tachycardia and dry mouth. He has no history of benign prostatic hyperplasia and reports of only being on one psychiatric medication. What type of psychiatric medication would cause such a side effect profile?
Cholinergic/Adrenergic drugs US Medical PG Practice Questions and MCQs
Question 191: A high-throughput screen to identify new sympathomimetic compounds was developed such that a transgenic line of cells was created that contained the alpha-1 (red), alpha-2 (yellow), beta-1 (green) and beta-2 (blue) receptors. When each of the receptors was activated a different fluorescent protein was expressed and new compounds with different properties could be identified by the fluorescence that they induced. Compound 7583 selectively induced the expression of the blue fluorescent protein. Which of the following known sympathomimetic medications if administered would similarly result in expression of only the blue fluorescent protein?
A. Albuterol (Correct Answer)
B. Fenoldopam
C. Epinephrine
D. Isoproterenol
E. Midodrine
Explanation: ***Albuterol***
- The blue fluorescent protein is expressed upon activation of the **beta-2 receptor**. Albuterol is a **selective beta-2 adrenergic agonist**.
- Its primary clinical use is as a **bronchodilator** in asthma and COPD, acting by relaxing bronchial smooth muscle via beta-2 receptor activation.
*Fenoldopam*
- Fenoldopam is a **D1 dopamine receptor agonist** used as a rapid-acting vasodilator.
- It has **no significant direct activity** at adrenergic alpha or beta receptors.
*Epinephrine*
- Epinephrine is a **non-selective adrenergic agonist** that activates alpha-1, alpha-2, beta-1, and beta-2 receptors.
- It would induce the expression of **all four fluorescent proteins** (red, yellow, green, and blue).
*Isoproterenol*
- Isoproterenol is a **non-selective beta-adrenergic agonist**, activating both beta-1 and beta-2 receptors.
- It would induce the expression of **green and blue fluorescent proteins**, but not exclusively blue.
*Midodrine*
- Midodrine is a **selective alpha-1 adrenergic agonist** and would induce the expression of the **red fluorescent protein**.
- It is primarily used to treat **orthostatic hypotension** by causing vasoconstriction.
Question 192: A 53-year-old man is brought by his daughter to the clinic. She lives a town away but visits often. She reports that on recent visits, his mood has been volatile, ranging from aggressive at some moments to depressed at others. She has noticed some new jerky movements which she has never seen before and has been quite forgetful. She is concerned that he might be abusing alcohol and drugs. What changes would you expect in the brain of this patient?
A. Decreased GABA at the caudate (Correct Answer)
B. Increased acetylcholine at the caudate
C. Decreased dopamine at the ventral tegmentum and substantia nigra pars compacta
D. Increased norepinephrine at the locus ceruleus
E. Decreased serotonin at the raphe nucleus
Explanation: ***Decreased GABA at the caudate***
- The patient's symptoms of **mood volatility**, **jerky movements (chorea)**, and **forgetfulness** are classic signs of Huntington's disease.
- Huntington's disease is characterized by the degeneration of **GABAergic neurons** in the **caudate nucleus** and putamen, leading to reduced inhibitory neurotransmission.
*Increased acetylcholine at the caudate*
- Huntington's disease is associated with **selective neuronal loss**, primarily of GABAergic neurons, not an increase in acetylcholine.
- While acetylcholine plays a role in movement, its increase in the caudate is not the primary pathology seen in Huntington's disease.
*Decreased dopamine at the ventral tegmentum and substantia nigra pars compacta*
- This description is characteristic of **Parkinson's disease**, where there is degeneration of dopaminergic neurons in the substantia nigra pars compacta.
- Parkinson's typically presents with **bradykinesia**, **rigidity**, and **tremor**, which are distinct from the patient's choreiform movements.
*Increased norepinephrine at the locus ceruleus*
- The locus ceruleus is a primary source of **norepinephrine** in the brain, playing a role in attention, arousal, and mood.
- Conditions involving altered norepinephrine levels in the locus ceruleus are not typically associated with the chorea and specific cognitive decline seen in this patient.
*Decreased serotonin at the raphe nucleus*
- The raphe nuclei are the main source of **serotonin** in the brain, involved in mood regulation, sleep, and appetite.
- While mood disturbances are present, decreased serotonin from the raphe nucleus is more typically associated with conditions like **depression**, and does not explain the characteristic chorea.
Question 193: A 61-year-old man with Alzheimer disease is brought to the emergency department 20 minutes after ingesting an unknown amount of his medications in a suicide attempt. He reports abdominal cramps, diarrhea, diaphoresis, and muscular weakness and spasms in his extremities. His temperature is 38.4°C (101.1°F), pulse is 51/min, respirations are 12/min and labored, and blood pressure is 88/56 mm Hg. Physical examination shows excessive salivation and tearing, and small pupils bilaterally. Treatment with atropine is initiated. Shortly after, most of his symptoms have resolved, but he continues to have muscular spasms. Administration of which of the following is the most appropriate next step in management of this patient?
A. Carbachol
B. Pancuronium
C. Benztropine
D. Physostigmine
E. Pralidoxime (Correct Answer)
Explanation: ***Pralidoxime***
- The patient's symptoms (abdominal cramps, diarrhea, diaphoresis, muscular weakness and spasms, bradycardia, hypotension, salivation, tearing, miosis) are consistent with **cholinergic toxicity** from overdose of cholinesterase inhibitor medications used for Alzheimer disease (e.g., donepezil, rivastigmine, galantamine). While atropine blocks muscarinic receptors and resolves many symptoms (salivation, diarrhea, bradycardia), it does not reverse the **nicotinic effects** (muscular spasms, weakness).
- Pralidoxime is a **cholinesterase reactivator** that works by detaching the inhibitor from acetylcholinesterase, restoring its function and reversing both muscarinic and nicotinic effects, especially the persistent muscular spasms.
*Carbachol*
- Carbachol is a **direct cholinergic agonist** that acts on both muscarinic and nicotinic receptors. Administering carbachol would worsen the existing cholinergic toxicity.
- It is used for conditions like glaucoma or postoperative urinary retention, not for treating cholinergic poisoning.
*Pancuronium*
- Pancuronium is a **nondepolarizing neuromuscular blocker** that prevents acetylcholine from binding to nicotinic receptors at the neuromuscular junction, causing muscle paralysis.
- While it would stop muscular spasms by inducing paralysis, it would not address the underlying cholinergic excess and would necessitate ventilatory support while the patient is already experiencing labored breathing. This is an inappropriate primary treatment for cholinesterase inhibitor overdose.
*Benztropine*
- Benztropine is an **anticholinergic agent** primarily used to treat Parkinson's disease and drug-induced extrapyramidal symptoms.
- While it has anticholinergic effects, its primary action is not potent enough to reverse severe cholinergic crisis, particularly the muscarinic effects already treated by atropine or the nicotinic effects causing spasms.
*Physostigmine*
- Physostigmine is a **reversible cholinesterase inhibitor** that increases acetylcholine levels at the synapse.
- This medication would exacerbate the patient's severe cholinergic poisoning, leading to a worsening of symptoms, and is contraindicated in this scenario.
Question 194: A 32-year-old man comes to the physician with involuntary lip smacking and hand and leg movements for the past two weeks. The movements are causing him difficulty walking and functioning at work. He has bipolar disorder treated with fluphenazine. Three months ago, he was hospitalized because of a manic episode, and his dosage was adjusted. Since then, he has not experienced a depressed mood, increased energy, irritability, or a change in his eating or sleeping patterns. He does not have suicidal or homicidal ideation. His temperature is 37.2°C (99°F), pulse is 75/min, and blood pressure is 126/78 mmHg. Examination shows repetitive lip smacking and dance-like hand and leg movements. His speech is not pressured, and his affect is appropriate. He is switched from fluphenazine to risperidone and his symptoms improve. Which of the following mechanisms explains this patient's improvement?
A. Weaker acetylcholine antagonism
B. Weaker serotonin antagonism
C. Weaker dopamine antagonism (Correct Answer)
D. Weaker acetylcholine agonism
E. Weaker histamine antagonism
Explanation: ***Weaker dopamine antagonism***
- The patient's symptoms (involuntary lip smacking, dance-like hand and leg movements) are consistent with **tardive dyskinesia**, a side effect of **long-term antipsychotic use**, particularly **first-generation antipsychotics** like fluphenazine.
- Tardive dyskinesia is thought to be caused by **hypersensitivity of dopamine receptors** in the basal ganglia due to prolonged dopamine receptor blockade. Switching to a **second-generation antipsychotic** like risperidone, which has weaker D2 antagonism, reduces this effect and can improve symptoms.
*Weaker acetylcholine antagonism*
- While fluphenazine has some anticholinergic effects, **acetylcholine antagonism** is primarily associated with side effects such as dry mouth, constipation, and blurred vision, not tardive dyskinesia.
- Stronger acetylcholine antagonism by antipsychotics can sometimes reduce **extrapyramidal symptoms (EPS)**, but tardive dyskinesia involves dopamine receptor changes.
*Weaker serotonin antagonism*
- Many antipsychotics, especially second-generation ones like risperidone, have **serotonin (5-HT2A) antagonism**, which is thought to contribute to their lower risk of EPS and better efficacy for negative symptoms.
- However, serotonin antagonism is not the primary mechanism by which risperidone improves tardive dyskinesia induced by potent D2 antagonism.
*Weaker acetylcholine agonism*
- **Acetylcholine agonism** is not a primary mechanism of action for typical or atypical antipsychotics.
- Medications that increase cholinergic activity might worsen some extrapyramidal symptoms, but this is not relevant to the improvement in tardive dyskinesia from switching to risperidone.
*Weaker histamine antagonism*
- Some antipsychotics, like olanzapine or quetiapine, have significant **histamine (H1) antagonism**, leading to side effects such as sedation and weight gain.
- However, histamine antagonism is not directly linked to the pathogenesis or improvement of tardive dyskinesia.
Question 195: A 28-year-old man is brought to the emergency department after his girlfriend found him twitching and jerking in the yard while gardening. Shortly after he became obtunded, emergency medical services reported 1 episode of emesis during transport. His blood pressure is 85/50 mmHg, pulse is 55/min, and respirations are irregular. Physical examination demonstrates marks on his left forearm, pinpoint pupils, diaphoresis, and fasciculations of his left calf. Following initial stabilization and respiratory support, what is the best next step?
A. Atropine
B. Naltrexone
C. Atropine and pralidoxime (Correct Answer)
D. Lamotrigine
E. Naloxone
Explanation: ***Atropine and pralidoxime***
* This patient presents with a classic picture of **organophosphate poisoning**, characterized by profuse secretions, bradycardia, hypotension, pinpoint pupils, and fasciculations.
* **Atropine** is given to block the muscarinic effects, and **pralidoxime** (2-PAM) is used to reactivate acetylcholinesterase, reversing both muscarinic and nicotinic effects.
* *Atropine*
* While essential for managing the **muscarinic effects** like bradycardia and profuse secretions, atropine alone does not address the nicotinic effects, such as muscle fasciculations and weakness.
* Without pralidoxime, the underlying cause of acetylcholinesterase inhibition is not treated, potentially leading to continued nicotinic toxicity.
* *Naltrexone*
* **Naltrexone** is an opioid receptor antagonist used for opioid dependence and alcohol use disorder.
* It has no role in the management of organophosphate poisoning, which involves cholinergic overstimulation.
* *Lamotrigine*
* **Lamotrigine** is an anticonvulsant medication used to treat epilepsy and bipolar disorder.
* The patient's seizures are secondary to organophosphate poisoning and would not be primarily managed with lamotrigine.
* *Naloxone*
* **Naloxone** is an opioid antagonist used to reverse opioid overdose.
* The patient's symptoms are inconsistent with opioid overdose and point strongly towards cholinergic crisis.
Question 196: A 72-year-old man comes to the physician with his son for a follow-up examination. The son reports that his father's mental status has declined since the previous visit when he was diagnosed with Alzheimer dementia. The patient often begins tasks and forgets what he was doing. He has increased trouble remembering events that occurred the day before and sometimes forgets names of common household objects. He has hypertension and hyperlipidemia. His current medications include lisinopril, hydrochlorothiazide, atorvastatin, and donepezil. He is confused and oriented only to person. He is unable to count serial sevens backward from 100. He is able to register 3 items but unable to recall them 5 minutes later. Which of the following is the most appropriate pharmacotherapy?
A. Memantine (Correct Answer)
B. Ginkgo biloba
C. Risperidone
D. Citalopram
E. Vitamin E
Explanation: ***Memantine***
- The patient exhibits features of **moderate to severe Alzheimer's disease**, as evidenced by significant cognitive decline and inability to recall items. Donepezil (an acetylcholinesterase inhibitor) is already being used; **memantine**, an **NMDA receptor antagonist**, is often added for moderate to severe stages to reduce excitotoxicity.
- Memantine helps by **modulating glutamate activity**, which is often dysregulated in Alzheimer's disease, thereby potentially improving cognitive function and behavioral symptoms or at least slowing decline.
*Ginkgo biloba*
- **Ginkgo biloba** is an herbal supplement sometimes touted for cognitive enhancement, but its efficacy in treating or slowing the progression of Alzheimer's disease is **not well-supported by robust clinical evidence**.
- It is **not a pharmacologically proven treatment** for established Alzheimer's dementia and would not be considered the most appropriate intervention for a patient with progressive decline already on a standard medication.
*Risperidone*
- **Risperidone** is an **antipsychotic medication** used to manage severe behavioral symptoms in dementia, such as psychosis, agitation, or severe aggression.
- While agitation might be present in dementia, the primary issue described is cognitive decline, and there's no mention of severe behavioral disturbances that would warrant the use of an antipsychotic, which carries significant **side effects** in elderly patients.
*Citalopram*
- **Citalopram** is a **selective serotonin reuptake inhibitor (SSRI)** primarily used to treat depression and anxiety.
- Although depression can coexist with Alzheimer's disease, the patient's symptoms are focused on cognitive decline and memory deficits, with no specific mention of depressive symptoms that would indicate citalopram as the most appropriate treatment for his current presentation.
*Vitamin E*
- **Vitamin E (alpha-tocopherol)** is an antioxidant that has been investigated for its potential neuroprotective effects in Alzheimer's disease.
- While high doses of vitamin E *might* offer a small benefit in slowing functional decline in some patients, its effect is **modest at best**, and it is not considered as effective or as primary a pharmacological intervention as memantine for moderate to severe Alzheimer's.
Question 197: A 45-year-old woman comes to the physician for the evaluation of persistent headaches for the last 2 months. The symptoms started insidiously. Menses had previously occurred at regular 28-day intervals with moderate flow. Her last menstrual period was 12 weeks ago. She is sexually active with her husband but reports decreased interest in sexual intercourse over the past few months. The patient does not smoke or drink alcohol. She is 168 cm (5 ft 6 in) tall and weighs 68 kg (150 lb); BMI is 24 kg/m2. She appears uncomfortable. Vital signs are within normal limits. A urine pregnancy test is negative. A pelvic ultrasound shows atrophic endometrium. A cranial MRI with contrast shows a 2-cm intrasellar mass. A hormone assay is performed and is positive. Which of the following is the most appropriate next step in the management?
A. Temozolomide therapy
B. Observation and outpatient follow-up
C. Cabergoline therapy (Correct Answer)
D. Radiotherapy
E. Biopsy of intrasellar mass
Explanation: ***Cabergoline therapy***
- The patient's symptoms (amenorrhea, decreased libido, headaches) and imaging findings (intrasellar mass) are highly suggestive of a **prolactinoma**. A positive hormone assay further strengthens this diagnosis.
- **Cabergoline** is a dopamine agonist and the first-line treatment for prolactinomas, effectively reducing prolactin levels and tumor size in most cases.
*Temozolomide therapy*
- **Temozolomide** is an oral alkylating agent used primarily for certain aggressive brain tumors like glioblastoma, or for recurrent/refractory pituitary adenomas that are not prolactinomas or have failed other treatments.
- It is not the initial treatment of choice for a newly diagnosed prolactinoma, which typically responds well to dopamine agonists.
*Observation and outpatient follow-up*
- Given the presence of symptomatic features (headaches, amenorrhea, decreased libido) and a 2-cm intrasellar mass, active management to reduce tumor size and prolactin levels is warranted.
- **Observation** is usually reserved for asymptomatic, small microprolactinomas (<10 mm) or those with minimal symptoms.
*Radiotherapy*
- **Radiotherapy** is generally reserved for prolactinomas that are resistant to medical therapy (dopamine agonists) or after surgical failure, and when conventional treatments have failed to control tumor growth or hormone secretion.
- It carries risks of side effects like hypopituitarism and optic nerve damage, making it unsuitable as a first-line treatment.
*Biopsy of intrasellar mass*
- A definitive diagnosis of prolactinoma can often be made based on elevated **prolactin levels** and characteristic imaging findings (intrasellar mass), making biopsy unnecessary in most cases.
- Pituitary biopsies are associated with morbidity and are typically reserved for atypical presentations or suspicion of malignancy.
Question 198: A 27-year-old woman comes to the physician for the evaluation of infertility. She has been unable to conceive for the past 2 years. Menses occur at 45 to 80-day intervals. She is 168 cm (5 ft 6 in) tall and weighs 77 kg (170 lb); BMI is 27.4 kg/m2. Physical examination shows facial acne and pigmented hair on the upper lip. Serum studies show elevated levels of testosterone and an LH:FSH ratio of 4:1. Treatment with the appropriate drug for this patient's infertility is begun. Which of the following is the primary mechanism of action of this drug?
A. Activation of pituitary dopamine receptors
B. Activation of granulosa cell aromatase
C. Activation of ovarian luteinizing hormone receptors
D. Inhibition of hypothalamic estrogen receptors (Correct Answer)
E. Inhibition of endometrial progesterone receptors
Explanation: ***Inhibition of hypothalamic estrogen receptors***
- The patient presents with classic symptoms of **polycystic ovarian syndrome (PCOS)**, including **oligomenorrhea** (menses every 45-80 days), **hirsutism**, **acne**, **elevated BMI**, **elevated testosterone**, and an **elevated LH:FSH ratio (4:1)**.
- **Clomiphene citrate** is the first-line drug for ovulation induction in PCOS patients with infertility.
- Clomiphene is a **selective estrogen receptor modulator (SERM)** that acts as a **competitive antagonist at estrogen receptors in the hypothalamus**.
- By blocking estrogen receptors, clomiphene prevents normal **negative feedback inhibition** of GnRH release.
- This results in increased **GnRH pulsatility**, leading to increased **FSH and LH secretion** from the anterior pituitary, which promotes **follicular development and ovulation**.
*Activation of pituitary dopamine receptors*
- This mechanism is characteristic of **dopamine agonists** (e.g., **bromocriptine**, **cabergoline**), which are used to treat infertility due to **hyperprolactinemia**.
- These agents activate D2 receptors in lactotroph cells, inhibiting prolactin secretion.
- The patient shows no signs of hyperprolactinemia (e.g., galactorrhea, amenorrhea from elevated prolactin).
*Activation of granulosa cell aromatase*
- Aromatase converts androgens to estrogens in granulosa cells.
- While aromatase activity is important in follicular development, **activating aromatase is not a mechanism of any standard ovulation-inducing drug**.
- In PCOS, there is often relative aromatase insufficiency, but drugs do not directly activate this enzyme for fertility treatment.
*Activation of ovarian luteinizing hormone receptors*
- While **exogenous LH or hCG** (which acts on LH receptors) may be used in assisted reproductive technology, this is not the mechanism of **first-line ovulation induction** in PCOS.
- Clomiphene works by increasing endogenous LH/FSH release, not by directly activating ovarian receptors.
*Inhibition of endometrial progesterone receptors*
- This is the mechanism of **mifepristone** (RU-486), an antiprogestin used for medical abortion and occasionally for **endometriosis** or **uterine fibroids**.
- Inhibiting progesterone receptors would **prevent implantation** or disrupt pregnancy, which is opposite to the goal of fertility treatment.
Question 199: A 64-year-old man is brought to the emergency department by his wife with a 2-hour history of diarrhea and vomiting. He says that he felt fine in the morning, but noticed that he was salivating, sweating, and feeling nauseated on the way home from his work as a landscaper. The diarrhea and vomiting then started about 10 minutes after he got home. His past medical history is significant for depression and drug abuse. His wife says that he has also been more confused lately and is afraid he may have ingested something unusual. Physical exam reveals miosis, rhinorrhea, wheezing, and tongue fasciculations. Which of the following treatments would most likely be effective for this patient?
A. Sodium bicarbonate
B. Naloxone
C. Atropine (Correct Answer)
D. Fomepizole
E. Ammonium chloride
Explanation: ***Atropine***
- This patient displays classic signs of **organophosphate poisoning**, characterized by **cholinergic crisis** (salivation, sweating, nausea, vomiting, diarrhea, miosis, rhinorrhea, wheezing, fasciculations). **Atropine** is a competitive antagonist of acetylcholine at muscarinic receptors and is the primary antidote, reversing most of these symptoms.
- The patient's profession as a **landscaper** increases his exposure risk, and the acute onset of symptoms supports a toxic exposure rather than an infection.
*Sodium bicarbonate*
- **Sodium bicarbonate** is primarily used to treat **metabolic acidosis**, such as in aspirin overdose or tricyclic antidepressant poisoning, or to alkalinize urine in certain toxic exposures.
- While metabolic acidosis can occur in severe organophosphate poisoning, it is not the primary treatment for the **cholinergic symptoms** themselves.
*Naloxone*
- **Naloxone** is an opioid antagonist used to reverse the effects of **opioid overdose**, characterized by respiratory depression, miosis, and central nervous system depression.
- The patient's symptoms of excessive secretions, gastrointestinal distress, and muscle fasciculations are inconsistent with opioid overdose.
*Fomepizole*
- **Fomepizole** is an alcohol dehydrogenase inhibitor used to treat **methanol and ethylene glycol poisoning**.
- These poisonings present with severe metabolic acidosis, visual disturbances (methanol), or renal failure (ethylene glycol), which are not the primary features described in this patient.
*Ammonium chloride*
- **Ammonium chloride** is an acidifying agent used to treat severe **metabolic alkalosis** or to increase the excretion of basic drugs.
- It is not indicated for the treatment of organophosphate poisoning and would likely exacerbate any existing acidosis.
Question 200: A 65-year-old male who is being treated for depression visits your emergency room complaining of being unable to urinate. In addition, the patient complains of tachycardia and dry mouth. He has no history of benign prostatic hyperplasia and reports of only being on one psychiatric medication. What type of psychiatric medication would cause such a side effect profile?
A. Tricyclic antidepressant (Correct Answer)
B. Serotonin norepinephrine reuptake inhibitor
C. Monoamine oxidase inhibitor
D. Selective serotonin reuptake inhibitor
E. Aminoketone
Explanation: ***Tricyclic antidepressant***
- The patient's symptoms of **urinary retention**, dry mouth, and tachycardia are characteristic **anticholinergic side effects**, frequently seen with TCAs.
- TCAs block muscarinic acetylcholine receptors, leading to these peripheral effects.
*Serotonin norepinephrine reuptake inhibitor*
- SNRIs primarily affect serotonin and norepinephrine reuptake and are less likely to cause severe anticholinergic effects like urinary retention.
- While they can cause some dry mouth or tachycardia due to noradrenergic effects, the combination with significant urinary retention points away from SNRIs.
*Monoamine oxidase inhibitor*
- MAOIs are generally associated with side effects such as **hypertensive crisis** (with tyramine-rich foods), orthostatic hypotension, and insomnia.
- They do not typically cause the prominent anticholinergic syndrome described.
*Selective serotonin reuptake inhibitor*
- SSRIs primarily affect serotonin reuptake and are known for side effects such as **gastrointestinal upset**, sexual dysfunction, and anxiety.
- They have a low affinity for muscarinic receptors and are less likely to cause significant anticholinergic effects like urinary retention.
*Aminoketone*
- Aminoketones (e.g., bupropion) typically act by inhibiting the reuptake of dopamine and norepinephrine.
- Common side effects include **insomnia**, agitation, and **seizure risk** at high doses; they do not typically produce the anticholinergic profile seen here.